Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

A pig kidney transplanted into a US man in 2025 functioned in his body for 271 days, marking the longest dialysis-free survival reported following a porcine kidney transplant, according to Harvard Medical School.

Tim Andrews, who was 66 at the time of the xenotransplantation, did not need dialysis for 271 days before receiving a human kidney from a deceased donor.

What Happened In The Case?

In January 2025, Andrews, received a genetically edited pig kidney, after being on dialysis for more than two years due to end-stage kidney disease. He became the fourth worldwide to receive a pig kidney.

Andrews received the genetically engineered pig kidney under an FDA Expanded Access Investigational New Drug application.

A team of doctors monitored him for kidney function, rejection, antibody development and potential pig-to-human infection, and found that the kidney began functioning immediately. An early episode of T-cell-mediated rejection resolved with treatment, and no pig pathogen transmission was detected, revealed the case published in the journal The Lancet.

After approximately six months, immunosuppression was reduced because of an infection. The xenotransplant subsequently developed microvascular injury and inflammation that progressed to organ failure.

In January this year Andrews received a deceased-donor human kidney, which showed immediate graft function, with no evidence of sensitization during follow-up.

What Did The Case Show?

The findings illustrate both the promise of xenotransplantation and the areas that still need improvement before pig organs can become a broader transplant option.

Importantly, the microvascular injury seen in the porcine kidney has implications for developing immunosuppressive strategies, donor genetic engineering and monitoring approaches in future clinical transplantation studies, the researchers said.

Xenotransplants And The Organ Transplant Gap

According to the latest data from the Global Observatory on Donation and Transplantation, a record 183,896 solid organ transplants were performed globally across 96 countries. This represents a 4% increase over 2024, primarily driven by an 11% rise in donations after circulatory death (DCD) and a 4% increase in living-donor transplants.

Despite this growth, a 90% unmet need remains a critical global issue as demand continues to rise, driven by chronic conditions such as diabetes and cardiovascular disease.

In the US alone, over 109,000 people remain on the national transplant waiting list, while an average of 12 people die every day waiting for a compatible match, according to HRSA Organ Donor Statistics.

India recorded a record 20,138 transplants, yet more than 89,000 patients are actively waitlisted, according to data from NOTTO. The deceased-donor rate remains critically low at 0.77 per million people, with deceased-donor organs accounting for only 18% of the country's total transplant pool.

“The organ shortage is the greatest crisis we have right now in transplantation,” said Leonardo Riella, associate professor of surgery at Mass General and medical director for kidney transplantation at Mass General Brigham.

“We know that the best treatment option for patients with end-stage kidney disease who have developed renal failure is transplantation, but we simply don’t have enough human organs to transplant in a timely manner.”

Andrews’ case therefore offers a potential way to help bridge this gap.

“Our vision is that xenotransplantation could help address this gap — initially as a bridge to get patients off dialysis while they wait for a human donor kidney, and potentially, as we establish long-term safety and durability, as a destination therapy in its own right,” Riella said.

Alcohol-attributable cancer deaths in the US doubled between 1990 and 2023, according to a study published in The Lancet Regional Health – Americas.

Using more than three decades of Global Burden of Disease data, researchers found that annual alcohol-attributable cancer deaths rose from 11,361 in 1990 to 23,126 in 2023.

Men and adults aged 55 and older experienced the greatest burden, but increases were seen across most cancer types, age groups and regions.

Among older men, liver cancer accounted for the highest alcohol-attributable mortality rates, followed by esophageal and colorectal cancers. Among women, breast cancer represented the leading source of alcohol-attributable cancer mortality.

Colorectal Cancer Leads In Younger Men

The study also identified concerning patterns among younger adults. For men aged 20 to 54, colorectal cancer was the leading alcohol-attributable cause of cancer death. Among women in the same age group, breast cancer ranked first, followed by colorectal cancer.

“Notably, among adults aged 20 to 54, colorectal cancer was the leading cause of alcohol-attributable cancer mortality in men and the second leading cause in women, surpassing liver cancer in both groups,” Jani said.

Alcohol And Cancer Risk

While it is commonly known that alcohol damages the liver, the new study highlights that its impact extends beyond liver cancer, with growing burdens from colorectal, breast, esophageal, pancreatic and other cancers.

Alcohol has long been recognized as a Group 1 carcinogen by the International Agency for Research on Cancer, in the same category as tobacco smoke and asbestos. Scientific evidence links alcohol consumption to cancers of the breast, liver, esophagus, colorectum and several head and neck sites.

“The most surprising finding was the breadth of alcohol’s potential impact across cancer types,” said Chinmay Jani, chief fellow in hematology and oncology at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

“Although its relationship with liver cancer is widely recognized, its contribution to cancers such as colorectal, esophageal, breast, pancreatic and prostate cancer is less well understood by the public.”

Alcohol As A Modifiable Risk Factor

Gilberto Lopes, chief of the Division of Medical Oncology at Sylvester, said the findings reinforce the importance of giving people clear information about lifestyle factors that influence cancer risk.

“What this study makes clear is that alcohol-related cancer risk is not limited to one disease or one group of people,” Lopes said. “As physicians and cancer researchers, we have an opportunity to help patients understand that alcohol is a modifiable risk factor and that even small, informed changes can be part of a broader strategy to reduce cancer risk in our community.”

Despite increasing scientific evidence, public awareness of the alcohol-cancer connection remains relatively low compared with awareness of other risk factors such as tobacco use.

“The most important takeaway is greater awareness that alcohol may affect cancer risk beyond the liver,” Jani said.

“These findings highlight alcohol as a potentially modifiable risk factor, and while the lowest safe dose is not yet known, this study suggests that reducing consumption to the lowest amount feasible for each individual may help lessen its impact on cancer risk and overall health.”

While GLP-1 drugs such as Ozempic, Wegovy and Zepbound are helping with weight loss and diabetes management, men already at risk of androgenetic alopecia may face a 7% higher risk of hair loss with higher GLP-1 activity, according to a new study.

Hair thinning has been reported by both men and women using GLP-1 drugs, with researchers largely attributing the shedding to rapid weight loss associated with the medications.

However, researchers at NYU Langone Health have now identified a potential genetic link between GLP-1 activity and androgenetic alopecia, an inherited form of hair loss affecting the top and front of the scalp.

"Our study provides the first genetic link between GLP-1 use and an increased risk of male-pattern hair loss from androgenetic alopecia, an association long suspected but until now not shown scientifically," said Lynn Petukhova, assistant professor in the Department of Dermatology and the Department of Population Health at NYU Grossman School of Medicine.

What Did The Study Find?

Researchers used large, publicly available genetic databases, including:

• eQTLGen: 31,684 mostly white men and women.
• Complex Traits Genetics group: 205,327 mostly white men

The researchers compared GLP1R-related genetic data with markers associated with androgenetic alopecia. They found that genetic variants linked to naturally higher levels of GLP-1 receptor proteins were more common in men with androgenetic alopecia.

The team also adjusted the analysis for hypertension, which may affect blood flow to the scalp and hair follicle growth; and accounted for insulin resistance and lower testosterone levels.

After these adjustments, the 7% higher risk remained.

Published online in the Journal of Investigative Dermatology, the findings suggest that GLP-1 activity and male-pattern hair loss may share a biological link.

Could Screening Help Prevent Hair Loss?

The findings could eventually help identify people who may be more vulnerable to hair loss before they are prescribed GLP-1 medications.

"Our findings suggest that, if future experiments prove successful, some men, and possibly women too, could be screened and benchmarked for their risk of hair loss before being prescribed GLP-1 medications," Petukhova said.

The researchers also suggested that some GLP-1 users could potentially receive combination treatments to prevent hair loss, such as minoxidil or another drug.

However, more research is needed to understand how GLP-1 activity may affect hair follicle growth. Petukhova also plans to investigate whether the genetic link seen in men applies to women.

Hair shedding has been reported among GLP-1 users and has been linked by researchers to rapid weight loss.

In many cases, hair growth resumes several months after weight stabilizes.

The new findings add a potential genetic explanation to these reports, but further research is needed to establish the underlying biological mechanism.

What Is Androgenetic alopecia?

Androgenetic alopecia is a common form of hair loss that becomes more likely with age. It can begin as early as the teenage years and affects both men and women, with hair loss in women most commonly observed after menopause.

Surveys suggest that 12% of Americans have used GLP-1 drugs specifically for weight loss, including one-fifth of women aged 50 to 64. Since Ozempic was approved by the US Food and Drug Administration in 2020, prescriptions for the medication have more than tripled.